SI
INBX

Sofinnova Investments’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Sofinnova Investments’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,302,645
Closed -$45.5M – 93
2024
Q1 		$45.5M Buy
1,302,645
+529,688
+69% +$19.3M 2.54% 12
2023
Q4 		$29.4M Buy
772,957
+29,663
+4% +$636K 1.64% 18
2023
Q3 		$13.6M Sell
743,294
-254,989
-26% -$5.34M 0.86% 33
2023
Q2 		$25.9M Sell
998,283
-246,205
-20% -$5.75M 1.7% 18
2023
Q1 		$23.5M Buy
1,244,488
+134,305
+12% +$3.12M 1.5% 18
2022
Q4 		$27.4M Buy
1,110,183
+660,006
+147% +$19.4M 1.62% 16
2022
Q3 		$8.08M Buy
450,177
+302,242
+204% +$5.45M 0.47% 36
2022
Q2 		$1.68M Sell
147,935
-366,705
-71% -$5.39M 0.14% 51
2022
Q1 		$11.5M Buy
514,640
+145,961
+40% +$3.73M 0.87% 29
2021
Q4 		$16.1M Buy
+368,679
New +$14.7M 0.94% 28

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Sofinnova Investments's INBX Position: Q2 2024 in Review

Sofinnova Investments sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 1,302,645 shares — an estimated $45.5M sold.

Sofinnova Investments first reported a position in INBX in Q4 2021 and held it in 10 quarters. The position peaked at $45.5M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Sofinnova Investments reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Sofinnova Investments sold 1,302,645 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $45.5M.
  • Sofinnova Investments first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 10 quarters.
  • Sofinnova Investments's Inhibrx, Inc. Common Stock position peaked at $45.5M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Sofinnova Investments's 13F filing for Q2 2024, filed 9 Aug 2024.